ClinicalTrials.gg
RecruitingNCT06392217Updated Nov 2, 2026

clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases

An observational study in Breast Cancer and Bone Metastases, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Fudan University · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Breast Neoplasms by Fudan University — 122 open to participants now, 142 under way, 31 of them phase 3. Breast Neoplasms · Fudan University.

Planned enrollment
15th of 60
500 · median 179
Started
2024
with 23 others
Observational
60 of 260
18 open now
Primary completion
2027-07
later than 79 of 141 live
Registered
159th of 260
by date

Among the 260 studies in Breast Neoplasms by Fudan University, this one is the 15th largest by planned enrollment of the 60 observational ones that give a count, is one of 24 that started in 2024, is one of 60 observational ones, reaches primary completion later than 79 of the 141 other live ones, and was the 159th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

122 of the 260 studies in Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

117 more — sign in →

By country, each count listing its studies:

All 122 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Breast Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This is a real-world study to explore the efficacy and safety of incadronate in the treatment of breast cancer patients with bone metastases.

03

Conditions studied

  • Breast Cancer
  • Bone Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

breast cancer patients with bone metastases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years or above;
  2. Can understand the purpose of clinical trials and the benefits and risks, voluntarily participate in and sign the
  3. The physical status score of the (ECOG) was ≤3;
  4. or cytologically confirmed breast cancer;
  5. Imaging or histocytology confirmed bone ;
  6. There were indications of useing Incadronate and no in the use of Incadronate;
  7. (NYHA)cardiac function grade ≤II, No serious heart disease;
  8. All women of childbearing age, fertile men or their spouses did not plan to have children or donate sperm throughout the trial period until 6 months after the last dose, or voluntarily took effective measures.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Patients with acute and chronic infections, or with other serious diseases at the same time, were judged not suitable for this study;
  3. Other malignant tumors within 5 years (except the following cases: cured skin basal cell carcinoma, cervical carcinoma in situ, thyroid papillary carcinoma; A second primary cancer that has been eradicated and has not recurred within five years; Investigators have identified the primary tumor source of the );
  4. Mental illness or mental disorder, poor compliance can not cooperate with and describe treatment response;
  5. There are serious organic diseases or major organ failure, such as decompensated heart, lung, liver, kidney failure, which can not tolerate treatment;
  6. Patients with bleeding tendency;
  7. The researcher believes that the patient has other conditions that are not suitable for participating in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The proportion of patients who had at least one Skeletal-related event(SRE)

    The proportion of patients who had at least one SRE within 12 months after initial treatment with infadronate (including pathological fractures, spinal cord compression, radiotherapy or surgery for bone metastases);

    Time frame: 12 months

  2. the time to first SRE

    The time from the first treatment with infadronate to the first observation of any SRE

    Time frame: 12 months

  3. Adverse events

    Incidence and classification of various adverse events of infadronate

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Yuxin Mu · Contact34778299
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 39 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Apr 2026 → Jul 2027 and completion Apr 2026 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2024
First posted
Apr 30, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Jul 1, 2027was Apr 2026
CompletionEst.
Jan 1, 2028was Apr 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University · Shanghai, China
Show 1 removed
  • Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University · Shanghai, China
Nov 2, 2026
Primary completion
Apr 1, 2026→Jul 1, 2027
Nov 2, 2026
Study completion
Apr 1, 2026→Jan 1, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University · Shanghai, China
    Show 1 removed
    • Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University · Shanghai, China
    Primary completion Apr 1, 2026→Jul 1, 2027
    Study completion Apr 1, 2026→Jan 1, 2028
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06392217
Lead sponsor
Fudan University
Responsible party
Jian Zhang,MD (Chief physician, Fudan University) — Principal investigator
First posted
Apr 30, 2024
Start date
Mar 12, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Jian Zhang
Contact
syner2000@163.com
+8664175590

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion